SS-31 (Elamipretide) is a mitochondria-targeting peptide currently being investigated for its ability to support mitochondrial function, cellular bioenergetics, and protection against oxidative stress. By selectively interacting with cardiolipin within the inner mitochondrial membrane, SS-31 helps preserve mitochondrial structure, improve ATP production, and reduce reactive oxygen species generation. As one of the most extensively studied mitochondrial-targeted peptides, SS-31 continues to demonstrate promising potential across both preclinical and clinical research involving cardiovascular health, neurodegeneration, skeletal muscle function, and age-related mitochondrial dysfunction.
Mitochondrial Research
Mitochondria-Targeting Peptide
Clinical & Preclinical
Mitochondrial Protection
SS-31, also known as Elamipretide, is a mitochondria-targeting peptide designed to selectively interact with cardiolipin, a phospholipid located within the inner mitochondrial membrane. By stabilizing mitochondrial structure and preserving the integrity of the electron transport chain, SS-31 supports efficient ATP production while reducing oxidative stress, making it one of the most extensively studied mitochondrial-targeted peptides in cellular bioenergetics and disease research.
Unlike many compounds that influence mitochondrial function indirectly, SS-31 acts directly at the inner mitochondrial membrane to improve mitochondrial efficiency and reduce the production of reactive oxygen species (ROS). Preclinical and clinical studies have demonstrated its potential to preserve cellular energy production, reduce oxidative damage, and support tissue function across cardiovascular, neurological, muscular, and age-related models of mitochondrial dysfunction.
Current research continues to investigate SS-31’s mechanism of action, mitochondrial signaling, long-term safety profile, and potential applications across cardiovascular disease, neurodegeneration, skeletal muscle disorders, kidney disease, healthy aging, and mitochondrial medicine. As with all compounds featured in the ChoicePeps Research Library, SS-31 is presented for educational and scientific reference purposes only.
Landmark Preclinical Research Demonstrating SS-31's Ability To Preserve Mitochondrial Function, Improve ATP Production, And Reduce Oxidative Damage In Cardiovascular Disease Models.
Clinical Research Evaluating Elamipretide (SS-31) Across Mitochondrial Disorders, Demonstrating Improvements In Cellular Bioenergetics, Skeletal Muscle Function, And Tissue Health.
Comprehensive Review Examining Mitochondrial Dysfunction, Cardiolipin Stabilization, Oxidative Stress, And The Therapeutic Potential Of Mitochondria-Targeting Peptides Including SS-31.
Current Research Summarizing SS-31's Effects On Mitochondrial Bioenergetics, Reactive Oxygen Species Reduction, Cellular Protection, And Cardiometabolic Health.
Current preclinical and clinical research is investigating SS-31 across several important areas of mitochondrial biology, cellular bioenergetics, oxidative stress, and cardiometabolic health.
SS-31 (also known as Elamipretide) is a mitochondria-targeting peptide designed to selectively bind cardiolipin within the inner mitochondrial membrane. By stabilizing mitochondrial structure and improving energy production, SS-31 has become an important investigational compound in research involving mitochondrial dysfunction, oxidative stress, cardiovascular disease, neurodegeneration, and healthy aging.
Unlike traditional peptides that act through hormone receptors, SS-31 works directly within mitochondria. It binds to cardiolipin, a phospholipid essential for normal mitochondrial function, helping improve electron transport chain efficiency, enhance ATP production, reduce excessive reactive oxygen species (ROS), and support overall cellular bioenergetics.
Researchers are interested in SS-31 because mitochondrial dysfunction contributes to numerous chronic diseases and age-related conditions. By improving mitochondrial efficiency while reducing oxidative damage, SS-31 has demonstrated potential across multiple areas of preclinical and clinical investigation involving cardiovascular health, muscle function, neuroprotection, kidney disease, and metabolic disorders.
SS-31 has been evaluated in numerous laboratory studies and human clinical trials examining mitochondrial biology, heart failure, skeletal muscle performance, kidney disease, inherited mitochondrial disorders, and age-related decline in cellular energy production. Research continues to investigate its effects on mitochondrial function, tissue protection, and long-term clinical outcomes.
Rather than binding traditional hormone receptors, SS-31 selectively targets cardiolipin, a phospholipid located on the inner mitochondrial membrane. Stabilizing cardiolipin helps preserve mitochondrial architecture, optimize ATP synthesis, reduce oxidative stress, and improve overall mitochondrial performance.
SS-31 (Elamipretide) has been investigated extensively in clinical research but is not currently FDA approved for general therapeutic use. Within the ChoicePeps Research Library, SS-31 is presented exclusively for educational and scientific reference purposes and is not intended for human consumption.
Current research continues to investigate SS-31 across numerous areas including mitochondrial diseases, cardiovascular health, skeletal muscle function, neurodegenerative disorders, kidney disease, metabolic dysfunction, healthy aging, exercise physiology, and long-term mitochondrial protection. Scientists are particularly interested in its ability to preserve cellular energy production and reduce oxidative stress across multiple organ systems.
The information presented in the ChoicePeps Research Library is provided solely for educational and informational purposes. Content is compiled from publicly available scientific literature and is intended to summarize current areas of research involving investigational compounds.
The material presented on this page has not been evaluated by the U.S. Food and Drug Administration (FDA) and should not be interpreted as medical advice, treatment recommendations, or evidence of clinical efficacy. Scientific understanding continues to evolve as additional laboratory and clinical research becomes available.
ChoicePeps does not make claims regarding the diagnosis, treatment, cure, or prevention of any disease. Visitors are encouraged to consult original peer-reviewed publications when reviewing scientific findings.
